Model selection for assessing the effects of doxorubicin on triple-negative breast cancer cell lines
From MaRDI portal
Publication:2105797
Recommendations
- Mathematical model of triple-negative breast cancer in response to combination chemotherapies
- Optimizing combination therapy in a murine model of HER2+ breast cancer
- A mathematical model of breast cancer treatment with CMF and doxorubicin
- Mathematical modeling of ER-positive breast cancer treatment with AZD9496 and palbociclib
- A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results
Cites work
- A Bayesian framework for adaptive selection, calibration, and validation of coarse-grained models of atomistic systems
- A hybrid ten-species phase-field model of tumor growth
- An efficient computational approach for prior sensitivity analysis and cross‐validation
- Continuum models of avascular tumor growth
- General diffuse-interface theories and an approach to predictive tumor growth modeling
- Information criteria and statistical modeling.
- Inverse Problem Theory and Methods for Model Parameter Estimation
- Model Based Inference in the Life Sciences: A Primer on Evidence
- Model Selection and Multimodel Inference
- Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression
- Selection and assessment of phenomenological models of tumor growth
- Selection and validation of predictive models of radiation effects on tumor growth based on noninvasive imaging data
Cited in
(3)
This page was built for publication: Model selection for assessing the effects of doxorubicin on triple-negative breast cancer cell lines
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2105797)
